Karuna Therapeutics

What Karuna Therapeutics does

Karuna Therapeutics was a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Boston, Massachusetts, that developed novel therapies for psychiatric and neurological conditions. The company's primary asset was COBENFY (xanomeline and trospium chloride), formerly known as KarXT, which works through selective activation of M1 and M4 muscarinic receptors in the brain—a fundamentally different mechanism from traditional dopamine-blocking antipsychotics. The drug originated from Eli Lilly's 1990s clinical trials and was revived by Karuna, which raised approximately $1.21 billion through public equity offerings in 2022 and 2023 to advance it through clinical development.

COBENFY received FDA approval in September 2024 as the first novel mechanism of action for schizophrenia in over 70 years, followed by China NMPA approval in December 2025. Bristol Myers Squibb acquired Karuna in late 2023 for approximately $14 billion to secure COBENFY as a cornerstone neuroscience asset addressing BMS's patent cliff concerns. Post-acquisition, COBENFY is commercialized through BMS's traditional pharmaceutical sales channels and multi-tiered distribution network, with Zai Lab holding exclusive Greater China commercialization rights. The company is no longer operating as an independent entity following the acquisition, but its lead asset continues under BMS development with Phase III trials underway for Alzheimer's disease psychosis expansion.

The underlying business model is prescription pharmaceutical sales through established wholesale distribution and healthcare provider channels, serving adult patients with schizophrenia and related psychotic disorders—an addressable market of approximately 8 million adults in China alone, plus significant US and global schizophrenia populations.

Name

Karuna Therapeutics

Legal name

Karuna Therapeutics, Inc.

Website

https://karunatx.com

Company type

Public

Founded year

2009

Operating status

Acquired

Headcount range

101–250 employees

Short description

Karuna Therapeutics was a clinical-stage biopharmaceutical company that developed COBENFY (xanomeline and trospium chloride), the first novel-mechanism schizophrenia therapy approved by the FDA in over 70 years, before being acquired by Bristol Myers Squibb for $14 billion in late 2023.

Ownership category

akta.pro rank

Product category

Central Nervous System Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Schizophrenia therapeutics
• Muscarinic receptor agonists
• Central nervous system drugs
• Psychiatric pharmaceuticals
• Neurological disease treatments

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Following FDA approval in September 2024, COBENFY generates revenue through prescription drug sales. Q1 results showed $56 million in Cobenfy revenue, indicating early commercial uptake. Zai Lab is pursuing separate commercialization in China following NMPA approval.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Karuna Therapeutics was a biopharmaceutical company that developed COBENFY (xanomeline and trospium chloride), a first-in-class muscarinic receptor agonist therapy approved by the FDA in September 2024 for the treatment of schizophrenia in adults. The drug works through selective activation of M1 and M4 receptors in the brain, offering a fundamentally different mechanism of action from traditional dopamine-blocking antipsychotics and representing the first new mechanism for schizophrenia approved in over 70 years.

Product overview

Karuna Therapeutics was a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders. The company's primary product was KarXT (later rebranded as COBENFY), a first-in-class muscarinic receptor agonist for schizophrenia that represented the first new mechanism of action for schizophrenia in over 70 years. Karuna Therapeutics was acquired by Bristol Myers Squibb for $14 billion in late 2023. COBENFY was approved by the FDA in September 2024 for schizophrenia and received approval in China in December 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• COBENFY (xanomeline and trospium chloride) COBENFY is a first-in-class schizophrenia therapy that works through selective activation of M1 and M4 receptors in the brain, offering a fundamentally different approach from traditional dopamine-blocking antipsychotics. It is prescribed for adults living with schizophrenia and addresses unmet need for treatment-resistant patients and those who cannot tolerate existing antipsychotic side effects.

Quantifiable outcome

• First new schizophrenia mechanism of action approved in over 70 years
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core and flagship.

• Zai LabcoreOEM/ Whitelabel/ Licensing Partner · 23 December 2025Zai Lab holds an exclusive license from Karuna Therapeutics (now BMS) to develop, manufacture, and commercialize COBENFY in Greater China. China's NMPA approved COBENFY for treating schizophrenia in adults in December 2025, making it the first schizophrenia therapy with a novel mechanism of action approved in over 70 years in China. Approximately 8 million adults in China live with schizophrenia.
• Bristol Myers SquibbflagshipStrategic or Co-development Partner · 1 January 2023Bristol Myers Squibb acquired Karuna Therapeutics for approximately $14 billion in late 2023. The acquisition was driven by BMS's need to replace expiring blockbusters and included Cobenfy (KarXT), which was approved for schizophrenia in September 2024. BMS is pursuing additional indications including Alzheimer's disease psychosis, representing a major strategic bet on neuroscience as BMS pivots from oncology toward neuropsychiatry.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Cerevel Therapeutics (acquired by AbbVie): Cerevel Therapeutics developed selective muscarinic M4 agonist emraclidine for schizophrenia, the closest direct competitor to Karuna's COBENFY mechanism. Acquired by AbbVie in 2024, emraclidine ultimately failed in Phase II trials, making Cerevel the most directly comparable CNS asset in the muscarinic space.
• Neurocrine Biosciences: Neurocrine is a CNS-focused biopharmaceutical company with Ingrezza (valbenazine) for tardive dyskinesia and a growing schizophrenia/neurology pipeline. Its commercial presence in CNS psychiatry channels makes it a direct peer in targeting the same psychiatrist prescriber base as COBENFY.
• Alkermes: Alkermes develops and commercializes CNS therapies including Lybalvi (olanzapine/samidorphan) for schizophrenia, competing directly with COBENFY in the antipsychotic market with a similar positioning focused on improved side-effect profiles over traditional dopamine blockers.
• Intra-Cellular Therapies (acquired by J&J): Intra-Cellular Therapies developed Caplyta (lumateperone), an approved schizophrenia and bipolar depression therapy acquired by Johnson & Johnson. Caplyta is one of the newest schizophrenia launches and the closest recent competitor to COBENFY in the novel-mechanism antipsychotic category.
• Axsome Therapeutics: Axsome Therapeutics developed Auvelity (dextromethorphan/bupropion) for major depressive disorder and is actively developing CNS therapies, including schizophrenia. Its positioning as a CNS-focused commercial-stage biopharma targeting psychiatry channels makes it a closely comparable peer.
• Acadia Pharmaceuticals: Acadia Pharmaceuticals commercializes Nuplazid (pimavanserin) for Parkinson's disease psychosis and has a CNS/neurology pipeline. It is a directly comparable CNS biopharma with first-in-class positioning in adjacent neuropsychiatric indications relevant to COBENFY's potential label expansions.
• Sumitomo Pharma (formerly Sumitomo Dainippon Pharma): Sumitomo Pharma commercializes Latuda (lurasidone), one of the leading branded atypical antipsychotics for schizophrenia, directly competing with COBENFY for psychiatrist prescriptions and market share in the schizophrenia treatment landscape.

Broad incumbents

• Otsuka Pharmaceutical: Otsuka markets Abilify Asimtufii and Rexulti, two major branded antipsychotics across schizophrenia and adjacent CNS indications. As a broad incumbent CNS pharmaceutical incumbent, Otsuka competes with COBENFY across the same psychiatric prescriber channels and patient populations.
• Bristol Myers Squibb (parent): BMS acquired Karuna for $14B in 2023 and now owns COBENFY. As parent and global commercialization partner, BMS's broader neuroscience, immunology, and oncology portfolio provides institutional context for COBENFY's positioning within a major biopharma pipeline.

Emerging players

• Sage Therapeutics (acquired by Biogen): Sage Therapeutics developed Zurzuvae (zuranolone) for postpartum depression and other neurosteroid-based CNS therapies. Its focus on first-in-class neuropsychiatric mechanisms makes it a comparable emerging CNS biopharma peer despite the different therapeutic approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/KarunaPharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds7 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karuna Therapeutics